Literature DB >> 21830944

Palmitoylethanolamide effects on intraocular pressure after Nd:YAG laser iridotomy: an experimental clinical study.

Nicola Pescosolido1, Aloisa Librando, Marta Puzzono, Marcella Nebbioso.   

Abstract

PURPOSE: The purpose of this article was to evaluate whether the anti-inflammatory agent palmitoylethanolamide (PEA) can counteract the increase of intraocular pressure (IOP) that may occur after neodymium-doped: yttrium aluminum garnet (Nd:YAG) laser iridotomy.
METHODS: Fifteen patients underwent bilateral laser iridotomy (Visulas YAG III Laser; Zeiss) for the prevention of primary closed-angle glaucoma. The IOP was measured at the beginning of the study (t-1), after 15 days of pretreatment with placebo or PEA (t0), and at 15, 30, and 120 min after the iridotomy (t1, t2, t3). The pretreatment consisted of 2 tablets of placebo or PEA per day for 15 days.
RESULTS: The t-test did not show a significant difference between the preoperative mean values of IOP t-1 and t0 in both the pretreatments. Analysis of variance/Tukey's test pointed out a significant increase of the postoperative IOP values in placebo pretreated patients (P≤0.05), but not in those who were pretreated with PEA. The trend analysis confirmed the significant positive trend in placebo pretreatment. The parallelism test between the 2 regressions showed a significant difference for the slopes (P=0.022) and not for the intercepts (P=0.520).
CONCLUSIONS: PEA can counteract the increase of IOP that occurs after iridotomy. It is likely that PEA controls the inflammatory process after iridotomy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21830944     DOI: 10.1089/jop.2010.0191

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  8 in total

1.  Nd: Yag laser iridotomy in Shaffer-Etienne grade 1 and 2: angle widening in our case studies.

Authors:  Sandra Cinzia Carlesimo; Luigi Di Santo; Pietro Bruni; Aloisa Librando; Antonietta Pompea Falace; Andrea Barbato
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

2.  Effects of palmitoylethanolamide on aqueous humor outflow.

Authors:  Akhilesh Kumar; Zhuanhong Qiao; Pritesh Kumar; Zhao-Hui Song
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-03       Impact factor: 4.799

3.  Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential.

Authors:  Earle R Nestmann
Journal:  Food Sci Nutr       Date:  2016-06-15       Impact factor: 2.863

4.  Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram.

Authors:  Gemma Caterina Maria Rossi; Luigia Scudeller; Chiara Lumini; Federica Bettio; Erica Picasso; Giulio Ruberto; Aba Briola; Alessandra Mirabile; Alessia Paviglianiti; Gian Maria Pasinetti; Paolo Emilio Bianchi
Journal:  Sci Rep       Date:  2020-06-26       Impact factor: 4.379

Review 5.  Cannabinoids in Glaucoma Patients: The Never-Ending Story.

Authors:  Andrea Passani; Chiara Posarelli; Angela Tindara Sframeli; Laura Perciballi; Marco Pellegrini; Gianluca Guidi; Michele Figus
Journal:  J Clin Med       Date:  2020-12-08       Impact factor: 4.241

Review 6.  Newer advances in medical management of glaucoma.

Authors:  Neethu Mohan; Arup Chakrabarti; Nazneen Nazm; Rajvi Mehta; Deepak P Edward
Journal:  Indian J Ophthalmol       Date:  2022-06       Impact factor: 2.969

Review 7.  Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy.

Authors:  Jan M Keppel Hesselink; Ciro Costagliola; Josiane Fakhry; David J Kopsky
Journal:  J Ophthalmol       Date:  2015-11-18       Impact factor: 1.909

Review 8.  Natural Products: Evidence for Neuroprotection to Be Exploited in Glaucoma.

Authors:  Annagrazia Adornetto; Laura Rombolà; Luigi Antonio Morrone; Carlo Nucci; Maria Tiziana Corasaniti; Giacinto Bagetta; Rossella Russo
Journal:  Nutrients       Date:  2020-10-16       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.